Former Aventis Exec Hofstaetter Finds A New Home At Wyeth
This article was originally published in The Pink Sheet Daily
Executive Summary
Thomas Hofstaetter is responsible for business and corporate development as a senior VP, reporting to Wyeth CEO Robert Essner and Pharmaceuticals President Bernard Poussot.
|
Former Aventis exec Thomas Hofstaetter, PhD, is Wyeth's new senior VP-corporate business development, effective Sept. 1. Hofstaetter is responsible for business and corporate development at Wyeth and reports to CEO Robert Essner and Pharmaceuticals President Bernard Poussot. Wyeth said Hofstaetter fills a position vacated by Hans Mueller, PhD, who retired earlier this year. Hofstaetter joins from Aventis, where he was senior VP-corporate development. He was expected to head up business development for the newly merged Sanofi-Aventis and was to hold one of the 18 seats on the management committee (1 (Also see "Sanofi-Aventis Picks Two To Head U.S.: Rothwell, Soriot On Management Committee" - Pink Sheet, 22 Jun, 2004.)). However, less than a week after the merger was completed Aug. 20, Sanofi announced Hofstaetter planned to resign (2 (Also see "Sanofi-Aventis Business Development Head Hofstaetter To Resign" - Pink Sheet, 26 Aug, 2004.)). Hofstaetter served as senior VP-business development and strategic planning for Aventis predecessor Hoechst Marion Roussel. - Lee Kalowski |